Pulmatrix, Inc. (NASDAQ:PULM) last traded at $2.10 seeing a daily low of $1.95 and a high of $2.38. The big move classifies the stock as one of the most volatile of the day.
Shares of the company are trading at $2.10 a great deal higher than $1.84, the stock’s 50 day moving average and which is quite a bit lower than the 200 day moving average of $2.52. The 50 day moving average was up $0.26 and the 200 day average was down $-0.42.
(NASDAQ:PULM) news items.
Pulmatrix Receives Award from Cystic Fibrosis Foundation Therapeutics to Support Development of PUR1900 for the Treatment of Pulmonary Fungal Infections
Pulmatrix Licenses Inhaled COPD Drug PUR0200 to Vectura Group plc
Pulmatrix to Present at the Rodman & Renshaw Global Investment Conference on September 11, 2017
Pulmatrix Receives Key Patents on its Inhaled Drug Delivery Technology and its COPD Drug.
Investors are a little more bearish on the company recently at least if you consider the uptick in short interest. The company experienced a rise in short interest of 7.56% as of August 31, 2017 from the last reporting period. Short shares increased from 1,543,186 to 1,659,925 over that timeframe. With short interest at 1,659,925 and short average daily volume at 159,600, days to cover is 10.0 and the percentage of shorted shares was 0.08% on August 31.
Pulmatrix, Inc., launched on September 25, 2013, is a clinical stage biopharmaceutical company developing inhaled therapies to address serious pulmonary disease. The Company?s product pipeline is focused on advancing treatments for rare diseases, including PUR1900, an inhaled anti-fungal for patients with lung disease, including cystic fibrosis. In addition, the Company focuses on pulmonary diseases through collaboration with partners, including PUR0200, a generic in clinical development for chronic obstructive pulmonary disease..